Precision Medicine in Parkinson's Disease Using Induced Pluripotent Stem Cells.

Autor: Kim MS; Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA., Kim H; Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA., Lee G; Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.; The Solomon Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Jazyk: angličtina
Zdroj: Advanced healthcare materials [Adv Healthc Mater] 2024 Aug; Vol. 13 (21), pp. e2303041. Date of Electronic Publication: 2024 Feb 11.
DOI: 10.1002/adhm.202303041
Abstrakt: Parkinson's disease (PD) is one of the most devastating neurological diseases; however, there is no effective cure yet. The availability of human induced pluripotent stem cells (iPSCs) provides unprecedented opportunities to understand the pathogenic mechanism and identification of new therapy for PD. Here a new model system of PD, including 2D human iPSC-derived midbrain dopaminergic (mDA) neurons, 3D iPSC-derived midbrain organoids (MOs) with cellular complexity, and more advanced microphysiological systems (MPS) with 3D organoids, is introduced. It is believed that successful integrations and applications of iPSC, organoid, and MPS technologies can bring new insight on PD's pathogenesis that will lead to more effective treatments for this debilitating disease.
(© 2024 Wiley‐VCH GmbH.)
Databáze: MEDLINE
Externí odkaz: